RR24. Long-Term Benefit of Open Renal Revascularization for Stent Failure  by Gifford, Shaun M. et al.
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 6S Abstracts 105SConclusions: Including SES in risk-adjustment for
readmissions after lower extremity revascularization would
impact the size of ﬁnancial penalties for low-SES serving
hospitals. This may have signiﬁcant implications for future
quality improvement initiatives at these institutions.
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Objectives: To determine long-term outcomes of pa-
tients needing open renal revascularization (ORR) for stent
failure.
Methods: Retrospective review was conducted of
consecutive patients operated on for renal stent failure
from 1998 to 2013. End points were hypertension, renal
function response, primary patency, reintervention, and
overall and hemodialysis (HD)-free survival.
Results: Of 878 ORR during this time, 37 patients
(70% female; mean age, 63 6 10 years) had 41 arteries
reconstructed for stent failure. Chronic kidney disease
(CKD) was stage 2 in 8%, stage 3 in 70%, stage 4 in
19%, and stage 5 in 3%. Reconstructions (bypass 84%)
were unilateral in 27 (mean glomerular ﬁltration rate
[GFR], 39.9 mL) and bilateral in 10 (mean GFR 47.1
mL). Twelve had ORR of a solitary kidney (mean GFR,
34.1 mL). Three procedure-related deaths occurred at
48, 65, and 210 days due to major adverse events. Over-
all, ﬁve patients needed HD (mean preoperative GFR
35.8 mL vs 43.7 mL in those without HD; P ¼ .29),
and three were permanent (8%). Over a mean follow-up
of 39 months (range, 2-112 months), mean systolic blood
pressure decreased from 153.9 to 134.3 mm Hg (P ¼
NS), and there was a signiﬁcant decrease in BP medica-
tions (2.98 before, 2.47 after; P ¼ .042). There was no
change in serum creatinine (1.54 mg/dL before; 1.62
mg/dL after), GFR (43.9 mL before; 45.8 mL after), kid-
ney length (10.6 cm before; 11.0 cm after), or CKD stage
(3.1 before and after). Two bypass grafts occluded, one at
5 days and the other at 18 months. One of these patients
needed HD, but both eventuated in renal transplant at 8
and 34 months, respectively. Three other grafts needed
four endovascular interventions for stenosis at 5, 13, 16,
and 17 months after operation. Primary patency was
82% at 5 years. Overall and HD-free survival was 85% at
5 years.
Conclusions: ORR for stent failure can be done safely,
is durable, requires few late interventions, and has excellent
freedom from HD. Patients may gain some improvement
in hypertension but have little change in renal function.
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Current Status of Symptomatic Nonatherosclerotic
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Objectives: To examine the epidemiology, treatment,
and outcomes of acute symptomatic nonatherosclerotic
mesenteric vascular disease (SNMVD) in a tertiary vascular
practice.
Methods: SNMVD was reviewed over a 6-year period
(2006-2012). Categories included embolism (EM), dissec-
tion (DI), and aneurysm (AN). Asymptomatic patients and
those with associated aortic pathology were excluded. Pre-
sentation, demographics, treatment, and outcomes were
recorded. Groups were compared with c2 and one-way
analysis of variance.
Results: Forty-six patients presented with SNMVD
(EM: 20, AN: 15, DI: 11). Age differed at presentation
(EM: 66.3 6 14.6, AN: 62.4 6 10.3, DI: 54.6 6 8.7
years; P < .05). Pain was the most frequent symptom
(EM: 100%, AN: 93%, DI: 91%; P ¼NS), with diarrhea be-
ing more frequent in EM (EM: 30%, AN: 7%, DI: 0%;
P < .05). EMs were more likely to affect the superior
mesenteric artery (SMA; EM: 80%, AN: 20%, DI: 45%; P
¼ .002), DI the hepatic artery (EM: 20%, AN: 13%, DI:
55%; P < .05), and AN SMA branches (EM: 5%, AN:
47%, DI: 0%; P ¼ .001). Males were more frequently
affected (EM: 80%, AN: 60%, DI: 73%; P ¼ NS). EMs
were more likely to have arrhythmia (EM: 40%, AN: 7%,
DI: 0%; P ¼ .008), with no other differences in pre-event
comorbidities or medications. The most common treat-
ment was surgical in EM (EM: 85%, AN: 33%, DI: 9%; P
< .001), endovascular (coiling or stenting) in AN (EM:
5%, AN: 40%, DI: 9%;P < .02), and conservative in DI
(EM: 15%, AN: 33%, DI: 82%). In-hospital mortality was
infrequent (EM: 10%, AN: 7%, DI: 0%; P ¼ NS). Mean
hospital length of stay differed by mechanism (EM: 13.6
days, AN: 9.2 days, DI: 2.3 days; P ¼ .005), although there
was a trend for increased readmission for DI (EM: 10%,
AN: 7%, DI: 36%; P ¼ .08). Mean follow-up was 14
months with no difference in 1-year survival (EM: 79%,
AN: 93%, DI: 100%; P ¼ NS).
Conclusions: Although EMs are the most common
cause of SNMVD, DI and AN are also common, but
with signiﬁcant differences in age, anatomic distribution,
and methods of treatment. With appropriate treatment,
1-year survival is excellent in all groups.
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